Microbot Medical Inc. (NASDAQ:MBOT - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Microbot Medical in a report issued on Thursday, April 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.15). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Microbot Medical's current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical's Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.40) EPS.
Microbot Medical Trading Up 1.2 %
NASDAQ:MBOT traded up $0.03 on Monday, hitting $2.49. 2,865,993 shares of the stock were exchanged, compared to its average volume of 2,088,283. The stock has a fifty day moving average of $1.70 and a 200-day moving average of $1.42. The stock has a market cap of $86.51 million, a PE ratio of -3.11 and a beta of 1.40. Microbot Medical has a fifty-two week low of $0.82 and a fifty-two week high of $3.38.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02).
Institutional Trading of Microbot Medical
A hedge fund recently bought a new stake in Microbot Medical stock. Renaissance Technologies LLC acquired a new position in Microbot Medical Inc. (NASDAQ:MBOT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 105,658 shares of the biotechnology company's stock, valued at approximately $118,000. Renaissance Technologies LLC owned approximately 0.52% of Microbot Medical as of its most recent SEC filing. 16.30% of the stock is owned by hedge funds and other institutional investors.
About Microbot Medical
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Read More
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
